atorvastatin has been researched along with allopurinol in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alcaino, H; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; López, R; Mellado, R; Navarro, M; Nogerol, C; Tapia, F; Verdejo, HE | 1 |
| Murphy, G; Murphy, JEJ; O'Gorman, SM; Powers, JM; Ralph, N | 1 |
| Athyros, VG; Giouleme, O; Grammatikos, N; Katsoula, A; Paschos, P; Tsimperidis, A | 1 |
| Kundzina, L; Lejniece, S | 1 |
| Adeyemi, DH; Afolabi, OA; Akhigbe, RE; Anyogu, DC; Hamed, MA; Odetayo, AF | 1 |
2 review(s) available for atorvastatin and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
Topics: Allopurinol; Atorvastatin; Biomarkers; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Factors; Treatment Outcome; Uric Acid | 2018 |
1 trial(s) available for atorvastatin and allopurinol
| Article | Year |
|---|---|
Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters.
Topics: Allopurinol; Atorvastatin; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Pyrroles; Regional Blood Flow; Treatment Outcome; Xanthine Oxidase | 2011 |
7 other study(ies) available for atorvastatin and allopurinol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Polypharmacy and sun exposure: Implications for mitochondrial DNA deletions in skin.
Topics: Aged; Allopurinol; Atorvastatin; Bisoprolol; Cholesterol; DNA Damage; DNA, Mitochondrial; Gene Deletion; Humans; Mitochondria; Perindopril; Pravastatin; Real-Time Polymerase Chain Reaction; Skin; Ubiquinone; Ultraviolet Rays | 2017 |
Klippel-Trenaunay-Weber syndrome with atypical presentation of hypersplenism and nephrotic syndrome: a case report.
Topics: Adult; Allopurinol; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Arteriovenous Fistula; Atorvastatin; Cholecalciferol; Erythrocyte Transfusion; Humans; Hypersplenism; Klippel-Trenaunay-Weber Syndrome; Male; Nephrotic Syndrome; Perindopril; Port-Wine Stain; Vitamins | 2017 |
Atorvastatin-mediated downregulation of VCAM-1 and XO/UA/caspase 3 signaling averts oxidative damage and apoptosis induced by ovarian ischaemia/reperfusion injury.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antioxidants; Apoptosis; Atorvastatin; Caspase 3; Down-Regulation; Female; Glutathione; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Ischemia; Malondialdehyde; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Reperfusion Injury; Tumor Necrosis Factor-alpha; Uric Acid; Vascular Cell Adhesion Molecule-1; Xanthine Oxidase | 2022 |